Artemisinin is undoubtedly the pride of the Chinese, and Tu Youyou has also won the Lasker Prize and the Nobel Prize, proving that Chinese can also make achievements in the field of medicine, but in terms of application, the situation of artemisinin is very embarrassing.

China's development time is too short, at the beginning of the international business rules do not know much, coupled with the international pharmaceutical giants to build an ultra-high threshold, resulting in domestic artemisinin-based drugs want to enter the international market is very difficult, and in 1994, Nova took the opportunity to buy the international sales rights of artemisinin-based compound drugs from the Chinese Academy of Medical Sciences, the original patent holder of artemisinin, at a low price, after five years of development, became the world's first pharmaceutical company to launch a fixed-dose artemisinin-based compound or combination of drugs.

Soon after, the World Health Organization recommended the use of combined artemisinin as the first antimalarial drug. Unfortunately, none of the Chinese pharmaceutical companies were GMP compliant, so Novartis became the only qualified supplier at the time and obtained a patent for artemisinin-derived compounds.

Since then, Sanofi of France has also obtained some relevant patents and launched its own artemisinin drugs, which has led to the monopoly of the international artemisinin market by Nova, Sanofi and Indian generic drugs, and foreign pharmaceutical giants occupy more than 90% of the international artemisinin drug market, while China's artemisinin drugs only occupy less than 10% of the share.

This is incompatible with China's status as an artemisinin-inventing country and absolute main producer of raw materials, and China has become a producer of artemisinin raw materials, which can only make meager profits under the pressure of international pharmaceutical giants.

Moreover, because Nova and Sanofi monopolize the artemisinin market, they not only have the pricing power of related drugs, but also continue to squeeze the purchase price of artemisinin raw materials, resulting in the continuous decline in the price of artemisinin raw materials, which means that most of the profits of the artemisinin industry are grabbed by Nova and Sanofi, and only a little residue is left to the country.

"The entry criteria for the pharmaceutical industry can be said to be set by those multinational pharmaceutical giants, and it must be difficult for us to enter; In fact, no matter which line is in a similar situation now, the same is true for the digital industry, mobile phones, computers, broadcast terminals, etc., the rules and standards are monopolized by developed countries, and it is very difficult for our enterprises to enter. Shen Long said, "However, there are some things that you will never have a chance if you don't do them, and only when you do them can you have hope." ”

Isn't that the case in the home appliance and mobile phone industries? After that, Chinese companies have gradually caught up with or even surpassed the enterprises in Europe, the United States, Japan and South Korea, and have a certain right to speak at the standard determination meeting, and in the future, they have launched advanced mobile phones leading foreign companies, and the road to the pharmaceutical industry is indeed more difficult than these industries, but we occupy the world's largest market, with unique patents in the world, not without opportunities.

"yes, hopefully that's going to be a good start." Director Qiao sighed, "What are you going to do next?" ”

"Let's send out the paper first, let the global industry know that we have made something that they failed to do, and then through Ron, they will stir up public opinion in the United States, and through the PR firm, they will expand their influence and get the FDA to accept our review request and conduct clinical trials." Shen Long said.

"I don't know much about the situation in the United States, but it sounds like you're very thoughtful and professional, so if you need help, just ask." Director Qiao was quite pleased, "It stands to reason that your achievement is fully qualified for the Nobel Prize, but it is difficult to say whether it can be won or not, and the Western scientific community has always been prejudiced against traditional Chinese medicine." ”

It would be nice if he could win the award in a short period of time, and using the influence of the Nobel Prize can undoubtedly speed up the process of passing the FDA review, but Shen Long thought that Tu Youyou invented artemisinin in the seventies, but he waited until 2015 to win the award, and even if he could win the award, it was estimated that he would have to wait for a long time.

It took Shen Long a few days to write a paper and submit it to the New England Journal of Medicine, which immediately shook the journal and they quickly distributed it to the authorities in the relevant field for review, and then published it in the fastest time.

As soon as the paper was published, it caused an uproar in the global pharmaceutical community, and the new drug launched by Shenlong was originally known only to Chinese medical practitioners to treat leukemia, but now, almost the whole world knows about it.

Many authoritative figures in the field have rushed to the magic capital, to Shenlong's medical hall and pharmaceutical factory to learn about the latest progress, when they saw the medical records of one patient after another, they were stunned, this achievement means that human beings have conquered a terminal disease, they did not think that this disease will be conquered, but they did not expect that this result will be made by a Chinese doctor, and it is still the way of traditional Chinese medicine.

"It's incredible that these patients are really under control and they're getting better." A senior professor from Hopkins University looked at the data that had just been detected and said, "Cheng, you have made a great achievement." ”

"This is not the result of my efforts alone, but the brilliance of traditional Chinese medicine." Shen Long did not monopolize this credit, "And Professor Ma Lin, Director Qiao, Mr. Weng and many other colleagues have also provided me with a lot of help." ”

"Cheng, such a miraculous drug should be available to patients all over the world, have you now begun to prepare for FDA review?" The professor at Harvard Medical School excitedly said that it is customary for pharmaceutical giants to bribe academia, but it does not mean that every medical authority is under their control, "If you have this plan, I am willing to help you." ”

"At present, the production scale of major raw materials is limited, and even the domestic demand cannot be completely solved, so I think we can wait a little longer." Shen Long didn't show too eagerness, "And, as far as I know, it seems very difficult for Chinese drugs to pass the FDA review." ”

"Cheng, science should not have borders, and patients in the United States need this medicine as well." The Harvard professor advised, "As for FDA review, I have a lot of experience in this area. ”

There are not only scholars who come to look for Shen Long, but also representatives of pharmaceutical companies, and this is not just Nova Company, these companies either threaten or induce, and they all want to get the patent for this drug from Shen Long.

"It is impossible to use patents on a global scale, and it is impossible to use overseas patents except for China, so you should change to more realistic conditions!" As I said before, Shen Long didn't want to repeat the mistake of artemisinin at all.